Matthew Kuehnle - Scientist - GSK | LinkedIn
Scientist. GSK. Aug 2020 - Present 4 years 1 month. Marietta, Pennsylvania, United States. • Perform cGMP testing of vaccines, utilites, and validation samples utilizing established methods....
- Title: Scientist at GSK
- Location: GSK
- Connections: 117
2 "Matthew Kuehnle" profiles | LinkedIn
View the profiles of professionals named "Matthew Kuehnle" on LinkedIn. There are 2 professionals named "Matthew Kuehnle", who use LinkedIn to exchange information, ideas, and...
Matthew Kuehnle Email & Phone Number | GSK Scientist
Matthew Kuehnle, based in Hummelstown, PA, US, is currently a Scientist at GSK. Matthew Kuehnle brings experience from previous roles at Subway, Lehigh University and Worldwide Lifecare Company. Matthew Kuehnle holds a 2016 - 2020 Bioengineering in Biopharmaceutical Engineering @ Lehigh University.
Board of directors and leadership team - GSK
Our board of directors is responsible for corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance. Our Chief Executive Officer is responsible for the management of the business and is assisted by the GSK leadership team (GLT). Each member is responsible for a specific ...
GSK strategic alliance with Vesalius Therapeutics | Davis Polk
3 days ago · Davis Polk advised GSK plc in connection with its multi-target strategic alliance with Vesalius Therapeutics, Inc. Vesalius will leverage its platform to identify novel intervention points in Parkinson’s disease and one additional indication in neurodegeneration and GSK will have the option to advance programs against those novel intervention points.
NeuRA chief executive recognised for groundbreaking brain …
2 days ago · Professor Matthew Kiernan has received the 2024 GSK Award for Research Excellence. How long will it be before devastating conditions like dementia can be effectively managed? According to Professor Matthew Kiernan, Chief Executive Officer and Institute Director at Neuroscience Research Australia (NeuRA), we could be on the cusp of major ...
Pharma company GSK quits BIO - STAT
Nov 8, 2024 · Several companies have quit BIO, and its lobbying spending has dropped. JUSTIN TALLIS/AFP via Getty Images. By John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle. Nov. 8, 2024 ...
Professor Matthew Kiernan AM awarded the 2024 GSK Award for …
Professor Matthew Kiernan AM, Chief Executive Officer and Institute Director at NeuRA and Scientia Professor of Neuroscience at UNSW has won the prestigious 2024 GSK Award for Research Excellence for his work in neurodegenerative diseases, particularly in motor neurone disease (MND) and frontotemporal dementia.. As an internationally renowned neuroscientist, Professor Kiernan is known for ...
GlaxoSmithKline focuses on immunology through collaboration
Mar 19, 2021 · GSK scientists are using the power of immunology, coupled with genetics and novel technologies, to find the next generation of interventions. The Immunology Network has an external board of advisors who come into GSK twice a year for Immunology Summits.
How GlaxoSmithKline is advancing efficient drug development …
GSK is developing an engineered T-cell receptor, T-cell immunotherapy designed to recognize a tumour-specific antigen and eliminate malignant cells in solid tumours and haematologic...